BioStem Technologies, Inc.

NASDAQ:BSEM

Biotechnology

Healthcare
$3.07 -6.54%

-$0.21 today

Market cap
$52.14M
Beta
0.26
P/E (TTM)
-1.8
EPS (TTM)
-$1.63
52W Low $2.25High $8.40

Volume 0.09M

Average 0.07M

BSEM EBITDA Margin

EBITDA as a percentage of revenue.

BioStem Technologies, Inc.NASDAQ: BSEM

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to -97.6%

EBITDA Margin was -97.6% in Q2 FY2026, down 98.0 pp from a year earlier. On a trailing-twelve-month basis it was 36.5%, up 28.9 pp year over year. Over 3 fiscal years it widened by 93.8 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -107.9% for the fiscal year ending Dec 2026, down from -1.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-97.6%+38.4 pp QoQ
Last fiscal yearDec 2025
-1.0%-11.4 pp YoY
LTMJun 2026
36.5%+28.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-98.0 pp-108.5 pp-10.5 pp
1 year-11.4 pp-106.9 pp-95.4 pp
3 years+93.8 pp+1.0 pp-92.9 pp
5 years+13.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1.0%
Year-over-year change
-11.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BSEM compares with its peers on the latest reported figures

No competitor EBITDA Margin figures are available to compare.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.34M6.88M16.69M301.83M47.48M
Cost of Revenue1.47M881.75K1.26M13.75M3.26M
Gross Profit2.87M5.99M15.42M287.86M44.22M
Gross Margin66.0%87.2%92.4%95.4%93.1%
Research & Development119.65K123.31K342K1.91M7.09M
Selling, General & Admin4.19M10.21M22.63M254.75M37.82M
Operating Expenses4.47M10.67M23.2M256.66M44.91M
Depreciation & Amortization283.9K243.42K229.02K293.22K219.42K
EBITDA(602K)(6.52M)(7.55M)31.49M(469.73K)
EBITDA Margin-13.9%-94.8%-45.3%10.4%-1.0%
Operating Income(1.61M)(4.68M)(7.78M)31.2M(689.15K)
Operating Margin-37.0%-68.1%-46.6%10.3%-1.5%
Interest Income0000413.85K
Interest Expense525.88K468.15K700.33K587.22K0
Other Income / Expenses193.93K(2.55M)(704.02K)(587.22K)299.5K
Income Before Tax(1.41M)(7.11M)(8.48M)30.61M(389.65K)
Pre-Tax Margin-32.5%-103.5%-50.8%10.1%-0.8%
Income Tax Expense000(1.27M)6.19M
Net Income(1.45M)(7.07M)(8.48M)31.88M(6.58M)
Net Margin-33.3%-102.9%-50.8%10.6%-13.9%
EPS (Basic)(0.12)(0.62)(0.62)1.95(0.39)
EPS (Diluted)(0.12)(0.62)(0.62)1.47(0.39)
Weighted Avg Shares11.69M11.41M13.71M16.37M16.73M
Weighted Avg Shares (Diluted)11.69M11.41M13.71M21.7M16.73M

BioStem Technologies, Inc.

NASDAQ:BSEM

Intrinsic Alpha fair value

Locked

Current Price

$3.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.